TransMedics raises 2026 revenue guidance to $764M-$774M as ENHANCE Part B and DENOVO catalysts shift to early 2027

Earnings Call Insights: TransMedics Group, Inc. (TMDX) Q3 2026

Management View

• "The third quarter of 2026 was the strongest in TransMedics' history for both revenue and case volume." (Founder, President, CEO & Director Waleed Hassanein)
• "Third quarter highlights include: total revenue

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.